logo
Share SHARE
FONT-SIZE Plus   Neg

Omeros: Ophthalmology Drug OMS302 Met Primary, Secondary Goals In Phase 3 Trial

Omeros Corp. (OMER) said its ophthalmology product OMS302 met its primary and secondary end points in Phase 3 clinical trial in patients undergoing intraocular lens replacement surgery.

According to the company, OMS302 achieved its primary endpoint by demonstrating statistically significant maintenance of intraoperative mydriasis, also called pupil dilation. OMS302 also showed statistical superiority over placebo in reduction of pain in the early postoperative period. The data for both endpoints are clinically meaningful.

OMS302, added to standard irrigation solution used during ophthalmological procedures, is Omeros' proprietary PharmacoSurgery product designed to maintain intraoperative mydriasis and reduce postoperative pain and irritation resulting from cataract and other lens replacement surgery.

"...This achievement marks our transition to a company preparing, rather than hoping, to commercialize our first product," said Gregory Demopulos, chairman and chief executive officer of Omeros. "Following our recent successful meetings with U.S. and European regulators, we plan to begin enrolling patients in our second Phase 3 trial early next month and to submit marketing applications in both the U.S. and Europe in the first part of 2013."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Zynga Inc. (ZNGA) on Thursday reported a first-quarter loss that narrowed from a year ago, reflecting an increase in revenues despite continued drop in user-base. Earnings for the quarter trumped analysts estimates, as did revenues, sending the company's shares up 13 percent in extended trading hours. San... Shares of Fitbit Inc. (FIT) slumped over 12 percent in extended hours trading after the maker of wearable technology reported a drop in first-quarter profit hurt largely by a surge in operating costs. The company also detailed a weak outlook for the second quarter. Fitbit's profit for the first-quarter... Twenty-First Century Fox Inc., (FOXA, FOX) on Wednesday reported a third-quarter profit that dropped from last year, as an increase in revenues were offset by higher operating costs. Earnings for the quarter came in line with Wall Street estimates, while revenues trumped expectations. Fox's third-quarter...
comments powered by Disqus
Follow RTT